Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
Applied DNA Sciences (NASDAQ:APDN) has issued a reminder to shareholders to cast their votes before the reconvening of a Special Meeting of Stockholders scheduled for February 14, 2025, at 11:00 a.m. The meeting, originally held on January 23, 2025, was adjourned due to lack of quorum.
The primary focus is the Warrant Exercise Proposal, which seeks approval for the exercisability of certain common stock purchase warrants and the issuance of underlying common stock. These warrants were issued during a securities offering on October 30, 2024. Shareholders of record as of November 25, 2024, who haven't yet voted can contact Kingsdale Advisors at 1-855-682-9644 or contactus@kingsdaleadvisors.com.
The proposal requires approval in accordance with Nasdaq Listing Rule 5635(d), as detailed in the Company's definitive proxy statement filed with the SEC on December 10, 2024.
Applied DNA Sciences (NASDAQ:APDN) ha ricordato agli azionisti di esprimere il loro voto prima della riconvocazione di un'Assemblea Straordinaria degli Azionisti prevista per 14 febbraio 2025, alle 11:00. L'incontro, originariamente tenutosi il 23 gennaio 2025, è stato sospeso per mancanza di quorum.
Il focus principale è sulla Proposta di Esercizio dei Warrants, che richiede l'approvazione per l'esercitabilità di determinati warrant per l'acquisto di azioni ordinarie e l'emissione delle azioni ordinarie sottostanti. Questi warrant sono stati emessi durante un'offerta di titoli il 30 ottobre 2024. Gli azionisti registrati al 25 novembre 2024, che non hanno ancora votato, possono contattare Kingsdale Advisors al numero 1-855-682-9644 o contactus@kingsdaleadvisors.com.
La proposta richiede approvazione in conformità con Nasdaq Listing Rule 5635(d), come dettagliato nella dichiarazione definitiva di delega depositata presso la SEC il 10 dicembre 2024.
Applied DNA Sciences (NASDAQ:APDN) ha enviado un recordatorio a los accionistas para que emitan sus votos antes de la reconvocatoria de una Reunión Especial de Accionistas programada para el 14 de febrero de 2025, a las 11:00 a.m.. La reunión, que se celebró originalmente el 23 de enero de 2025, se suspendió debido a la falta de quórum.
El enfoque principal es la Propuesta de Ejercicio de Warrants, que busca la aprobación para el ejercicio de ciertos warrants de compra de acciones ordinarias y la emisión de acciones ordinarias subyacentes. Estos warrants se emitieron durante una oferta de valores el 30 de octubre de 2024. Los accionistas registrados a partir del 25 de noviembre de 2024, que aún no hayan votado, pueden contactar a Kingsdale Advisors al 1-855-682-9644 o contactus@kingsdaleadvisors.com.
La propuesta requiere aprobación de acuerdo con la Regla de Cotización 5635(d) de Nasdaq, como se detalla en la declaración de poder definitiva presentada ante la SEC el 10 de diciembre de 2024.
Applied DNA Sciences (NASDAQ:APDN)는 주주들에게 2025년 2월 14일 오전 11시로 예정된 특별 주주총회가 다시 소집되기 전에 투표를 할 것을 상기시켰습니다. 이 회의는 2025년 1월 23일에 처음 개최되었으나, 정족수 미달로 연기되었습니다.
주된 초점은 워런트 행사 제안으로, 특정 보통주 매수 워런트의 행사 가능성과 기본 보통주의 발급 승인을 요청하는 것입니다. 이 워런트는 2024년 10월 30일에 실시된 증권 제공 중에 발행되었습니다. 2024년 11월 25일 기준으로 등록된 주주 중 아직 투표하지 않은 분들은 Kingsdale Advisors에 1-855-682-9644 또는 contactus@kingsdaleadvisors.com으로 연락하실 수 있습니다.
이 제안은 Nasdaq 상장 규칙 5635(d)에 따라 승인을 받아야 하며, 이는 2024년 12월 10일 SEC에 제출된 회사의 최종 위임장 성명서에 자세히 설명되어 있습니다.
Applied DNA Sciences (NASDAQ:APDN) a rappelé aux actionnaires de voter avant la reconvocation d'une Assemblée Générale Spéciale des Actionnaires prévue pour le 14 février 2025, à 11h00. La réunion, initialement prévue le 23 janvier 2025, a été suspendue en raison d'un manque de quorum.
L'accent principal est mis sur la Proposition d'Exercice des Warrants, qui demande l'approbation pour l'exercice de certains warrants d'achat d'actions ordinaires et l'émission d'actions ordinaires sous-jacentes. Ces warrants ont été émis lors d'une offre de titres le 30 octobre 2024. Les actionnaires inscrits au 25 novembre 2024, qui n'ont pas encore voté, peuvent contacter Kingsdale Advisors au 1-855-682-9644 ou contactus@kingsdaleadvisors.com.
La proposition nécessite une approbation conformément à la Règle de Cotation 5635(d) de Nasdaq, comme détaillé dans la déclaration de procuration définitive de l'entreprise déposée auprès de la SEC le 10 décembre 2024.
Applied DNA Sciences (NASDAQ:APDN) hat Aktionäre daran erinnert, ihre Stimmen vor der Wiederberufung einer Sonderaktionärsversammlung abzugeben, die für 14. Februar 2025, um 11:00 Uhr angesetzt ist. Die ursprünglich am 23. Januar 2025 abgehaltene Sitzung wurde aufgrund mangelnder Beschlussfähigkeit vertagt.
Der Schwerpunkt liegt auf dem Vorschlag zur Ausübung von Warrants, der die Genehmigung für die Ausübarkeit bestimmter Optionsscheine auf Stammaktien und die Ausgabe der zugrunde liegenden Stammaktien beantragt. Diese Warrants wurden während einer Wertpapieremission am 30. Oktober 2024 ausgegeben. Aktionäre, die am 25. November 2024 im Aktienregister stehen und noch nicht abgestimmt haben, können Kingsdale Advisors unter 1-855-682-9644 oder contactus@kingsdaleadvisors.com kontaktieren.
Der Vorschlag bedarf der Genehmigung gemäß Nasdaq Listing Rule 5635(d), wie in der endgültigen Proxyerklärung des Unternehmens, die am 10. Dezember 2024 bei der SEC eingereicht wurde, detailliert dargestellt.
- None.
- None.
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m.
The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@kingsdaleadvisors.com.
The Special Meeting was originally held on January 23, 2025, but, due to a lack of quorum, was adjourned to allow additional time for the Company's stockholders to vote on Proposal One (the "Warrant Exercise Proposal") set forth in the Company's definitive proxy statement (the "Proxy Statement") filed with the U.S. Securities and Exchange Commission on December 10, 2024: to approve, in accordance with Nasdaq Listing Rule 5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October 30, 2024.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
YOUR VOTE IS IMPORTANT!
Your vote is important, and we ask that you please vote "FOR" the Warrant Exercise Proposal.
For specific instructions on how to vote your shares, please refer to the instructions on the Notice of Internet Availability of Proxy Materials you received in the mail, the section entitled "About the Special Meeting" beginning on page 1 of the Proxy Statement or, if you request to receive printed proxy materials, your enclosed proxy card. Please note that shares held beneficially in street name may be voted by you in person at the Special Meeting only if you obtain a legal proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares.
If you have any questions or require any assistance with voting your shares, please call the Company's proxy solicitor, Kingsdale Advisors, at:
1- 855-682-9644 (toll free) or 1-646-491-9095 (call or text outside North America) or by email at contactus@kingsdaleadvisors.com
Additional Information
In connection with the Company's Special Meeting, the Company has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to the shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. A copy of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, including financial statements and any financial statement schedules required to be filed in accordance with SEC rules, will be sent without charge to any stockholder of the Company requesting it in writing from: Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Beth Jantzen. We also make available, free of charge on our website, all of our filings that are publicly filed on the SEC's EDGAR website, including Forms 10-K, 10-Q and 8-K, at www.adnas.com.
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com
X: @APDN
SOURCE: Applied DNA Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Applied DNA's (APDN) Special Meeting of Stockholders reconvening?
What is the Warrant Exercise Proposal that APDN shareholders are voting on?
Why was Applied DNA's original Special Meeting on January 23, 2025 adjourned?
What is the record date for APDN shareholders to be eligible to vote?
How can APDN shareholders submit their votes for the Special Meeting?
